Login to Your Account



NewCo News

Inhibrx Inks Potential $500M Antibody License with Celgene

By Marie Powers
Staff Writer

Thursday, June 28, 2012
Just two years after its launch, privately held Inhibrx LLC hooked Celgene Corp. in its first antibody license. The deal for the undisclosed target potentially could exceed $500 million, including up-front, clinical and regulatory milestone payments and royalties on commercial sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription